Bli medlem
Bli medlem

Du är här

2016-05-12

Nordic Nanovector: Nordic Nanovector ASA: First Quarter 2016 Results Presentation and Webcast

Date: 12.05.2016        Press Release no: 23/2016

Oslo, Norway, 12 May 2016

Nordic Nanovector ASA (OSE: NANO), a company focusing on the
development and commercialisation of novel targeted therapeutics in
haematology and oncology, will announce its first quarter 2016
results on Thursday, 19 May 2016.

A presentation by Nordic Nanovector's senior management team will take
place at 8:30 am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: NYLAND

The presentation will be recorded as a webcast and will be available
at www.nordicnanovector.com in the section: Investor
Relations/Webcast.

The results report and the presentation will be available at
www.nordicnanovector.com in the section:

Investor Relations/Reports and Presentation/Quarterly Reports/2016
from 7:00 am CEST the same day.

###

For further information, please contact:

Luigi Costa, Chief Executive Officer

Cell: +41 79 124 8601

Email: ir@nordicnanovector.com

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 282 2948/+44 207 282 2949

mark.swallow@citigatedr.co.uk / david.dible@citigatedr.co.uk

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37
antibody (HH1) conjugated to a low intensity radionuclide (lutetium-
177). It has shown promising efficacy and a favourable safety profile
in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient
population. The Company is aiming at developing Betalutin® for the
treatment of major types of NHL with first regulatory submission
anticipated in 1H 2019. Nordic Nanovector intends to retain marketing
rights and to actively participate in the commercialisation of
Betalutin® in core markets, while exploring potential distribution
agreements in selected geographies. The Company is committed to
developing its ARC pipeline to treat multiple selected cancer
indications. Further information about the Company can be found at
www.nordicnanovector.com

-----------------------------------------------------------
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--first-...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.